モチヅキ タケシ
Mochidzuki Takeshi
望月 猛 所属 医学部 医学科(東京女子医科大学病院) 職種 助教 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. |
掲載誌名 | 正式名:Modern rheumatology 略 称:Mod Rheumatol ISSNコード:14397609/14397595 |
掲載区分 | 国外 |
巻・号・頁 | 29(3),pp.413-417 |
著者・共著者 | Mochizuki Takeshi†, Ikari Katsunori, Yano Koichiro, Sato Motoaki, Okazaki Ken |
担当区分 | 筆頭著者 |
発行年月 | 2019/05 |
概要 | OBJECTIVE:To examine the deterioration of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with abatacept over the long-term.METHODS:We examined 131 patients with RA who had been treated with abatacept for more than 1 year. All patients underwent high-resolution computed tomographic (HRCT) scanning of the chest before administration of abatacept, and we examined deterioration of ILD over a follow-up period after administration of abatacept was initiated.RESULTS:Eleven patients (8.4%) showed deterioration of ILD over a mean follow-up period of 47.8 months. The factors related to ILD deterioration were use of methotrexate (MTX) [odds ratio 12.75, 95% confidence interval (CI) 1.09-148.77], and change in Krebs von-den Lungen-6 (odds ratio 1.00, 95% CI 1.00-1.01), according to multivariate logistic regression analysis.CONCLUSION:MTX in patients with RA treated with abatacept was a risk factor for deterioration of ILD. Discontinuation of MTX should be considered one of treatment reduction to prevent the deterioration of ILD. |
DOI | 10.1080/14397595.2018.1481566 |
PMID | 29798700 |